Clarus Therapeutics Holdings, Inc.

Operating margin

—

Net margin

−291.0%

Return on equity

255.1%

Return on assets

−78.6%

Return on capital (ROCE)

—

Liabilities / assets

130.8%

Debt / equity

—

Book value / share

$-0.66

Revenue growth (YoY)

119.1%

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Accruals / assets

6.1%moderate

Piotroski F-Score

1/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Bankruptcy or receivership · Completed an acquisition or disposition · Modified shareholder rights · Change in control · Director / officer change · Other material eventMar 1, 2023
• Regulation FD disclosureFeb 22, 2023
• Regulation FD disclosureJan 24, 2023
• Regulation FD disclosureDec 22, 2022
• Regulation FD disclosureNov 23, 2022
• Entered a material agreement · Completed an acquisition or disposition · Director / officer change · Other material eventOct 31, 2022
• Regulation FD disclosureOct 24, 2022
• Other material eventOct 18, 2022

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.